Transforming growth factor-
1 downregulation of Smad1 gene expression in rat hepatic stellate cells
Hong Shen,1
Guojiang Huang,3
Mohammed Hadi,2
Patrick Choy,2
Manna Zhang,3
Gerald Y. Minuk,3
Yongping Chen,1 and
Yuewen Gong1,2,3
1Faculty of Pharmacy and Departments of
2Biochemistry and Medical Genetics and
3Internal Medicine, Faculty of Medicine, University of
Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
Submitted 10 October 2002
; accepted in final form 23 May 2003
 |
ABSTRACT
|
---|
Smads are intracellular signaling molecules of the transforming growth
factor-
(TGF-
) superfamily that play an important role in the
activation of hepatic stellate cells (HSCs) and hepatic fibrosis. Excepting
the regulation of Smad7, receptor-regulated Smad gene expression is still
unclear. We employed rat HSCs to investigate the expression and regulation of
the Smad1 gene, which is a bone morphogenetic protein (BMP) receptor-regulated
Smad. We found that the expression and phosphorylation of Smad1 are increased
during the activation of HSCs. Moreover, TGF-
significantly inhibits
Smad1 gene expression in HSCs in a time- and dose-dependent manner.
Furthermore, although both TGF-
1 and BMP2 stimulate the activation of
HSCs, they have different effects on HSC proliferation. In conclusion, Smad1
expression and phosphorylation are increased during the activation of HSCs and
TGF-
1 significantly inhibits the expression of the Smad1 gene.
transforming growth factor-
; Smad1; regulation
THE INTRACELLULAR SIGNALING molecules of the transforming growth
factor-
(TGF-
) superfamily are a large and conserved family known
as Smads (33). All members of
the TGF-
superfamily signal through highly conserved transmembrane
receptors and Smads. Binding of ligand to the type II transmembrane
serine-threonine kinase receptor recruits and phosphorylates the type I
receptor kinase. After activation of the type I receptor, receptor-activated
Smads (R-Smads) are recruited as direct substrates for the kinase activity of
the type I receptor. Phosphorylated R-Smads then dissociate from the membrane
and join common-mediated Smads (Co-Smads) to form heteromeric complexes that
translocate into the nucleus, where they mediate transcriptional responses on
target genes (1,
22). Interactions between
R-Smads and type I receptors are specific. Smad2 and Smad3 interact only with
receptors for TGF-
or activin, whereas Smad1, Smad5, and Smad8 interact
only with receptors for bone morphogenetic proteins (BMPs)
(23). Additionally, all
R-Smads appear to share Co-Smad4, and resources of Co-Smad4 are limited within
the cell (32).
BMPs are the largest family within the TGF-
superfamily and are
involved in several important processes in development. Three Smad proteins
have been shown to signal for receptors of the BMP family: Smad1, Smad5, and
Smad8. Smad1 was the first mammalian Smad gene to be cloned, whereas Smad5 and
Smad8 are two highly conserved vertebrate isoforms. Smad1 is phosphorylated
and activated by the BMP receptors BMPR-1A and BMPR-1B, activin receptor
(ActR-1), and ActR-like kinase 1 (ALK1)
(15,
26). Both Smad1 and Smad5 are
important in the induction of ventral mesoderm formation in Xenopus.
Targeted disruption of Smad5 indicates a role of this gene in vascular
development and patterning, although mutant embryos undergo normal
gastrulation (3). Targeted
disruption of Smad1 in embryonic stem cells and generation of mutant mice
reveals that Smad1-null mice proceed through gastrulation normally but die in
midgestation due to defects in allantois development and chorioallantoic
placenta formation (14).
However, the role of Smad1 in the activation of hepatic stellate cells (HSCs)
and the regulation of Smad1 gene expression are poorly understood. In this
study, we describe an increased expression of Smad1 during in vitro activation
of rat HSCs and TGF-
1 downregulation of Smad1 expression in these
cells.
HSCs are nonparenchymal liver cells, which comprise
15% of the total
number of resident cells within the liver. They play a key role in the
development of liver fibrosis and cirrhosis. In normal liver, they are the
principle storage sites for retinoids
(8). Following liver damage or
inflammation, HSCs undergo a process known as activation, which is the
transdifferentiation of quiescent, retinoid-storing cells into proliferative,
matrix-producing, and contractile myofibroblast-like HSCs
(2,
25). One of the characteristic
features of activated HSCs is the increased expression and release of
TGF-
1, which in turn plays an autocrine role in stimulation of
fibrogenic extracellular matrix production and perpetuation of HSC activation
(11).
 |
MATERIALS AND METHODS
|
---|
Materials. Collagenase D, pronase, DNase, and monoclonal
antibodies against smooth muscle
-actin (
-SMA) and desmin were
purchased from Roche Diagnostics (Laval, QC, Canada). Recombinant human
TGF-
1 and human BMP2 were purchased from R&D Systems (Minneapolis,
MN). DMEM, FBS, and TRIzol LS Reagent were from GIBCO-BRL (Burlington, ON,
Canada). Other chemicals were purchased from Sigma-Aldrich Canada (Oakville,
ON, Canada). Antibody against Smad1 (06-653) and phospho-Smad1
(Ser463 and Ser465) were purchased from Upstate
Biotechnology (Lake Placid, NY). Donkey anti-rabbit IgG (NA934), sheep
anti-mouse IgG (NA931), and the enhanced chemiluminescence Western blotting
kit were purchased from Amersham Pharmacia Biotech (Baie d'Urfe, QC, Canada).
Advantage RT-for-PCR kit, Advantage cDNA PCR kit, and polymerase mix were
purchased from Clontech Laboratories (Palo Alto, CA). Human hepatocellular
carcinoma cells (PLC/PRF/5 cells) were kindly provided by Dr. Alan McLachlan
(Research Institute of Scripps Clinic at La Jolla, La Jolla, CA).
Rat HSCs. Male Sprague-Dawley rats (450-550 g body wt) were
provided by Central Animal Care of the University of Manitoba and maintained
under 12:12-h light-dark cycles with food and water ad libitum. During the
research described in this report, all animals received humane care in
compliance with the institution's guidelines (Animal Protocol no. 98-053),
which are in accordance with the Canadian Council on Animal Care's criteria.
HSCs were isolated by two steps of collagenase and pronase methods
(29). Briefly, the rat liver
was perfused with 0.125 mg/ml collagenase D, 0.5 mg/ml pronase, and 20
µg/ml DNase I in Hanks' balanced salt solution supplemented with 10 mmol/l
HEPES and 4.2 mmol/l sodium bicarbonate for 15 min. After in situ perfusion,
the liver was removed, separated, and incubated with 0.125 mg/ml collagenase D
and 0.5 mg/ml pronase for another 15 min with constant low-speed stirring at
37°C. After hepatocytes were removed, HSCs were separated from other
nonparenchymal cells by centrifugation on 11.3% Nycodenz with sodium chloride.
HSCs were harvested from the interface between suspension buffer and 11.3%
Nycodenz solution, washed, and plated on uncoated plastic tissue culture
dishes (Costar) at a density of 25,000 cells/cm2. Purity of HSC
preparation (>97%) was assessed by typical light microscopic appearance and
vitamin A-specific autofluorescence. Cells were cultured in DMEM supplemented
with 10% FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mmol/l
L-glutamine at 37°C in a humidified atmosphere of 5%
CO2-95% air. The first change of medium was made 24 h after
seeding, and the second change of the medium was
20 h later.
Microphotography. Freshly isolated primary HSCs and
differentiative HSCs were imaged and photographed on an Olympus inverted-phase
microscope (CK-40) using a mounted Olympus 35-mm camera (Carsen Group,
Markham, ON, Canada) and TMAX 400 Kodak black-and-white film (Eastman Kodak,
Rochester, NY).
Protein isolation and Western blot analysis. Cell nuclear protein
was isolated by Nuclei EZ prep kit (Sigma-Aldrich Canada). Primary HSCs at
different days treated with or without TGF-
1 and BMP2 were washed with
ice-cold PBS, scraped from the dishes, centrifuged at 500 g for 5 min
at 4°C, and lysed in Nuclei EZ lysis buffer. Nuclei were isolated
according to the protocol described by the manufacturer, and the supernatant
was collected as cytoplasmic protein. The nuclei were further lysed in protein
extraction buffer (1x = 10 mmol/l Tris · HCl, pH 7.5, 1 mmol/l
EDTA, pH 8.0, 10 mmol/l NaCl, 1% SDS, 1 mmol/l PMSF, and 0.25 mol/l sucrose)
(12). Whole cellular protein
was extracted by dissolving cells in the protein extraction buffer as
described previously (12).
Protein concentration was measured by the Lowry method
(9). Twenty micrograms of
protein (nuclear protein, cytoplasmic protein, or whole cell protein) was
mixed with 4x gel-loading buffer (4x = 250 mmol/l Tris ·
HCl, pH 6.8, 8% SDS, 20% glycerol, 0.2% bromophenol blue, and 5%
-mercaptoethanol), separated on 12% SDS-polyacrylamide gel under
reducing conditions, and transferred onto Nitroplus-2000 membranes (Micron
Separations, Westborough, MA). Nonspecific antibody binding was blocked by
preincubation of the membranes in 1x Tris-buffered saline containing 5%
skim milk for 1 h at room temperature. Membranes were then incubated overnight
at 4°C with antibodies against
-SMA, Smad1, and phospho-Smad 1 at
different dilutions in 1 x Tris-buffered saline containing 2% skim milk.
After being washed, they were incubated with donkey anti-rabbit IgG at 1:1,000
dilutions for 1 h at room temperature. Bands were visualized by employing the
enhanced chemiluminescence kit per the manufacturer's instructions.
Transient transfection of rat Smad1 cDNA in Chang liver cells. Rat
Smad1 cDNA was cloned in pcDNA3.1 mammalian expression vector (kindly provided
by Dr. K. M. Mulder, Pennsylvania State University, State College, PA) and
transfected into Chang liver cells (American Type Culture Collection,
Manassas, VA) by FuGene 6 reagent (Roche, Mississauga, ON, Canada). After
transfection, the cells were incubated in serum-free DMEM for 24 h, and then
medium was changed to fresh serum-free DMEM with or without 10 ng/ml of BMP2.
Chang liver cells were incubated with or without BMP2 for 30 min, and the
nuclear proteins were isolated by Nuclei EZ prep kit. The nuclear protein was
employed for gel electrophoresis and Western blot analysis. The loading
control of Western blot analysis was performed with lysate of the same samples
and incubated with an antibody against histone H1.
Northern blot analysis of Smad1 mRNA abundance. TRIzol LS reagent
was employed to extract total RNA of HSCs as described in the manufacturer's
manual. Northern blot analysis was performed by using
[
-32P]dCTP-labeled full-length rat Smad1 and 18S cDNA probes
as previously described (12).
Briefly, 40 µg of total RNA was separated through 1% agarose gel,
transferred onto GT-zeta nylon membranes (Bio-Rad, Burlington, ON, Canada),
hybridized overnight with the probes, and washed as per the manufacturer's
instructions.
RT-PCR. Total RNA was isolated as described above from 3-, 6-, and
10-day cultured HSCs. The first-strand cDNA was synthesized by an Advantage
RT-for-PCR kit. Briefly, 1 µg of total RNA was dissolved in
diethylpyrocarbonate-treated doubled-distilled water (ddH2O) to
achieve a final volume of 12.5 µl. Subsequently, 1 µl oligo(dT) primer,
4 µl of 5 x reaction buffer, 1 µl of 10 mmol/l dNTP mix, 0.5 µl
recombinant RNase inhibitor, and 1 µl Moloney murine leukemia virus reverse
transcriptase were added and incubated for 1 h at 42°C. At the end of the
reverse transcription procedure, the reaction mixture was heated to 94°C
for 5 min and brought up to a final volume of 100 µl with ddH2O.
PCR was performed by using the Advantage PCR kit, polymerase mix, and
oligonucleotides synthesized by GIBCO-BRL. The specific primers for rat Smad1
were designed from the rat Smad1 sequence (GenBank accession no. U66478
[GenBank]
) by
the Oligo 5.1 program on a Macintosh computer. The sense primer was
5'-TCCTACCTTTCCGAACCGAAGA-3' (positions 179-201), and the
antisense primer was 5'-GAGGTCAAGTATCACGGATCCTTTAC-3'
(positions 1778-1804). The expected size of products was 1,625 base
pairs. The specific rat GAPDH amplimers were from Clontech (5507-3), and the
expected size of GAPDH was 986 base pairs. PCR amplification was carried out
by applying 32 cycles comprising denaturation at 94°C for 1 min, annealing
at 59.5°C (Smad1) and 60°C (GAPDH) for 30 s, elongation at 72°C
for 4 min, followed by a final elongation at 72°C for 8 min using an
Eppendorf MasterCycler (Eppendorf, Westbury, NY). PCR products were analyzed
by electrophoresis in a 1.5% agarose gel. Identity of PCR products was
confirmed by sequencing at the DNA-sequencing facility of the Manitoba
Institute of Cell Biology.
Real-time RT-PCR quantitation of mRNA. Quantitation of mRNA was
performed by LightCycler following real-time RT-PCR protocol provided by Roche
Molecular Biochemicals. Briefly, full-length rat Smad1 cDNA was inserted into
a pCR2.1 vector (Invitrogen Canada, Burlington, ON, Canada). The sense mRNA of
rat Smad1 was synthesized by a Ribo-probe Combination System-T3/T7 (Promega,
Madison, WI) with T7 polymerase. The synthesized sense mRNA of rat Smad1 was
employed as template for a standard curve. Total RNA and the first-strand cDNA
were prepared as described above. One microgram of the first-strand cDNA was
employed for real-time RT-PCR quantitation of Smad1 with sense primer
5'-CCGCCTGCTTACCTGCCTCCTGAA-3' (positions 685-709) and
antisense primer 5'-GAACGCTTCGCCCACACGGTTGT-3' (positions
863-886). Real-time RTPCR was performed with LightCycler-DNA Master SYBR
Green I kit from Roche Molecular Biochemicals in the following protocol:
denaturation at 95°C for 2 min; amplification at 40 cycles of 1 s at
94°C, 10 s at 62°C, and 16 s at 72°C; and melting curve analysis
at 58°C for 10 s at the end of each cycle. The amount of Smad1 mRNA was
calculated with a computer program and represented as nanograms per
milli-liter of standard RNA.
Cell proliferation assay. Cell proliferation was measured by a
[3H]thymidine incorporation method. After isolation of HSCs,
primary HSCs were placed in 12-well plates and the medium was first changed
after 24 h. HSCs were then incubated with fresh DMEM with 2% FBS and either
TGF-
1 or BMP2 for 6 days. The media and reagents were changed every
other day. At the end of treatment, HSCs were labeled with 10 µCi of
[3H]thymidine (specific activity 45 Ci/mmol; Amersham, Oakville,
ON, Canada) for 2 h, fixed in 10% trichloroacetic acid, and lysed in 400 µl
of 0.2 M sodium hydroxide. One hundred microliters of the cell lysate was
employed to measure [3H]thymidine incorporation with a LKB liquid
scintillation counter (Wallac, Turku, Finland), and 10 µl of the cell
lysate was used to measure protein content by the Lowry technique.
Statistical analyses. To analyze differences in the treatment
groups, we performed ANOVA and Fisher's protected least significant
differences test as a post hoc test using StatView software (version 5.0; SAS
Institute, Cary, NC). Differences with P values <0.05 were judged
to be significant.
 |
RESULTS
|
---|
HSC activation and expression of Smad1. Rat HSCs were isolated and
cultured in vitro as shown in Fig.
1. Figure
1A displays rat HSCs at 2 days after isolation, and
Fig. 1B shows the
cells at 9 days after isolation. One of the features of HSCs is that they can
spontaneously activate in vitro when cultured on uncoated plastic dishes.
Whole cellular protein was extracted from rat HSCs at different times after
isolation, and the expression of
-SMA, a marker of activation of HSCs,
was demonstrated in Fig.
1C, which showed the increases in expression of
-SMA after 9- and 12-day culture in vitro.
The effects of TGF-
on HSCs and expression of Smad2, Smad3, and Smad4
in HSCs are the important research areas in liver fibrosis. It has been
documented that Smads play an important role in TGF-
regulation of HSC
proliferation and activation. However, Smads, which are involved in BMP
signaling, have not been of major research interest until recently. By
employing antibodies against Smad1, we documented that expression of Smad1 was
elevated during the activation of HSCs
(Fig. 2A). To
demonstrate the specificity of antibody against phospho-Smad1, Chang liver
cells were transfected with full-length rat Smad1 cDNA and incubated with or
without BMP2 for 30 min. As shown in Fig.
2B, BMP2 increased phospho-Smad1 expression in the
nuclear extract of these cells. In addition, specificity of Smad1 antibody was
confirmed by transfecting Smad1 into Chang liver cells. As shown in
Fig. 2C, transfected
cells expressed more Smad1 than non-transfected cells. To further examine
whether or not the elevated Smad1 protein was due to an increase in the
expression of Smad1 mRNA, we extracted the total RNA from HSCs and performed
RT-PCR with a pair of specific primers for rat Smad1
(Fig. 3A).
Quantitative real-time RT-PCR was also performed to document the quantity of
Smad1 mRNA in HSCs (Fig.
3B). There was a significant increase in Smad1 RNA
transcript after 6-day culture in vitro. The level of Smad1 RNA transcript
remained elevated at 9 days after in vitro culture.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 2. Expression of Smad1 during in vitro activation of HSCs and specificity of
phospho-Smad1 antibody. Cell extracts were isolated from different times of
HSC in vitro culture as indicated. A: Western blot analysis. Sixty
micrograms of protein was loaded on SDS-PAGE gel for electrophoresis. Protein
was transferred onto nitrocellular membranes, which were incubated with
antibodies against Smad1 and phospho-Smad1. B: specificity of
antibody against phospho-Smad1. Chang liver cells were transiently transfected
with rat Smad1 cDNA and incubated with or without 10 ng/ml bone morphogenetic
protein (BMP) 2 for 30 min. Sixty micrograms of nuclear protein was loaded on
SDS-PAGE gel for electrophoresis. Protein was then transferred onto
nitrocellular membranes, which were incubated with phospho-Smad1 antibody.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3. RT-PCR and quantitative real-time RT-PCR analyses of Smad1 mRNA abundance
during in vitro activation of HSCs. A: analysis of RT-PCR in HSCs
during in vitro activation. B: quantity of Smad1 mRNA in HSCs.
Experiments were performed 3 times with consistent observation.
*P < 0.05.
|
|
TGF-
regulation of Smad1 gene expression in HSCs.
One of the most important findings in this study is that TGF-
1 decreased
the expression of Smad1. When rat HSCs were incubated with TGF-
1 for 3,
6, and 12 days, the abundance of Smad1 and phospho-Smad1 was reduced in a
consistent manner (Fig. 4). To
further confirm TGF-
1 regulation of Smad1, we isolated rat HSCs and
treated these cells with TGF-
1. The abundance of Smad1 mRNA and protein
were documented by Northern and Western blot analyses. After rat HSCs were
cultured for 6 days and incubated with TGF-
1 in fresh culture media
without serum, Smad1 RNA transcript was decreased in a time-dependent manner
(Fig. 5). The level of Smad1
mRNA reached a nadir after 24 h of TGF-
1 treatment. The TGF-
1
inhibition of Smad1 mRNA level was not observed in a human hepatocellular
carcinoma cell line (PLC/PRF/5 cells). When rat HSCs were treated with
different concentrations of TGF-
1 for 12 h, the abundance of Smad1 mRNA
and protein was decreased with an increase in TGF-
1 concentrations
(Fig. 6). In addition, the
antibody employed in this experiment was the antibody against Smad1, not
phospho-Smad1, which indicates that TGF-
1 downregulated Smad1 protein
but not phosphorylation of Smad1.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4. Expression of Smad1 and phospho-Smad1 during in vitro activation of HSCs.
Nuclear proteins were isolated from HSCs at days indicated in the presence or
absence of transforming growth factor (TGF)- 1 (1 ng/ml). Expression of
Smad1 and phospho-Smad1 was analyzed by Western blot as described in
MATERIALS AND METHODS. The typical Western blot pictures are shown
in A, and the densitometric data are plotted in B. The
experiments were performed on 3 different occasions.
|
|
Smads are usually cytoplasmic proteins. However, after Smads are activated
by BMPs or TGF-
receptors, Smads will migrate to the nuclei. To document
whether Smad1 was translocated in the nuclear compartment with or without
TGF-
1 treatment, HSCs after 9-day in vitro culture were treated with or
without TGF-
1. Nuclear and cytoplasmic proteins were isolated and
analyzed for both Smad1 and phospho-Smad1. As shown in
Fig. 7, phospho-Smad1 was only
present in the nuclear fraction but Smad1 can be observed in both nuclear and
cytoplasmic fractions of cells.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 7. Location of Smad1 and phospho-Smad1 in HSCs. Both nuclear and cytoplasmic
proteins were isolated from 9-day primary cultured HSCs in the presence or
absence of TGF- 1 (1 ng/ml). Sixty micrograms of protein was employed for
Western blot analysis with antibodies against Smad1 and phospho-Smad1. Human
hepatoblastoma HepG2 cells were employed as control.
|
|
TGF-
and BMP regulation of HSC proliferation and
activation. Since Smad1 is the signaling molecule of BMP and TGF-
1,
TGF-
regulation of Smad1 expression may affect the biological activity
of TGF-
on HSCs. We examined the regulation of HSC proliferation and
activation by TGF-
1 and BMP2. Primary HSCs were treated with different
concentrations of TGF-
1 and BMP2 for 6 days. TGF-
1 significantly
inhibited HSC proliferation, whereas BMP2 did not affect the proliferation of
HSCs (Fig. 8). In addition,
after primary HSCs were incubated with TGF-
1 or BMP2 for 6 days, both
cytokines increased the abundance of
-SMA protein, with BMP2 tending to
induce more
-SMA than TGF-
1 in these cells
(Fig. 8).
 |
DISCUSSION
|
---|
Smad1 is activated by the receptors for BMPs as well as TGF-
1
(18,
19). The function of Smad1 is
to mediate signal transduction of BMPs and TGF-
. Recent studies from
Smad1 transgenic mice reveal early post-natal lethality in transgenic mice and
impaired cell cycle in embryonic fibroblasts derived from these animals
(24). Smad1 knockout mice die
in midgestation due to defects in allantois development and chorioallantoic
placenta formation (14). The
observation of increased expression of Smad1 during the culture of HSCs
suggests a role for Smad1 in the activation of HSCs. It is not clear whether
Smad1 directly mediates the activation of HSCs or acts through the signal
transduction of BMPs. The expression and role of BMP in the activation of HSCs
are poorly understood. In this study, we observed that BMP2 had no effect on
HSC proliferation but that it did elevate the level of
-SMA protein in
HSCs. These results suggest that BMPs may play an important role in
transdifferentiation of HSCs. This is consistent with the function of BMPs in
development, because BMPs and Smad1 are required for bone and heart formation
in vertebrates (30).
Studies investigating the regulation of Smad1 are limited to Smad1
phosphorylation. It is known that Smad1 is phosphorylated after binding of
BMPs to their receptors (20).
Studies from Mulder's group
(20) indicate that Smad1 can
be phosphorylated by TGF-
1. Moreover, they reveal that Ras and MEK are
partially required for Smad1 phosphorylation by both TGF-
1 and BMPs
(35). In addition, it has been
documented that epidermal growth factor and hepatocyte growth factor could
phosphorylate Smad1 through an ERK-mediated pathway to inhibit BMP-mediated
nuclear accumulation and transcriptional activation of Smad1
(17). Our observations of
TGF-
1 downregulation of Smad1 mRNA and protein levels indicate a new
regulatory mechanism of Smad1 gene expression. The role of Smad1 in HSCs
remains to be further explored; however, it has been documented that Smad2,
Smad3, and Smad4 remained constant during the activation of HSCs
(7,
31).
The causative role of TGF-
in hepatic fibrosis has been provided by
studies in transgenic mice and also in genetic transfer of active TGF-
1
by adenoviral vector. Chronic expression of active hepatic TGF-
1 in
transgenic mice through the hepatocyte-specific promoters phosphoenolpyruvate
caboxykinase (4) and albumin
(16) resulted in hepatic
fibrosis. On the other hand, gene transfer of active TGF-
1 by adenoviral
vector also results in fibrosis in the lung and the liver. Moreover, blocking
TGF-
action by soluble TGF-
receptors
(10,
34) inhibits hepatic fibrosis
in rats and mice. It remains to be determined whether these actions will alter
Smad1 expression.
The causative role of TGF-
in HSC activation has been provided from
studies of HSCs in vitro and in vivo. It has been documented that TGF-
induces transdifferentiation of HSCs into myofibroblasts
(13) and inhibits
proliferation of HSCs (27).
However, contrasting observations regarding TGF-
regulation of HSC
proliferation and transdifferentiation exist. It has been documented that
TGF-
1 inhibits quiescent HSC proliferation but does not affect activated
HSC proliferation (6). Loss of
the TGF-
1 inhibition of activated HSC proliferation appears to be
related to loss of TGF-
1 binding on surface receptors of the cells. A
similar effect of TGF-
1 regulation of collagen I expression was observed
in quiescent and activated HSCs
(13). However, our results
indicate that TGF-
1 still inhibits subcultured (for 18 days) HSC
proliferation. Moreover, TGF-
1 slightly increases
-SMA expression
in HSCs. The discrepancies may be due to the culture condition and the state
of HSC differentiation. In our experiments, 10% FBS was employed, whereas in
other experiments 0.1% FBS was used
(6). TGF-
1 may just
inhibit the stimulated effect of FBS or growth factors in the FBS on HSCs. It
has been known that TGF-
1 reverses the stimulating effect of
platelet-derived growth factor on HSC proliferation
(5). Moreover, the role of
TGF-
1 in the HSCs is still unclear, because in mice with TGF-
1
gene knockout HSCs can still be activated when cultured in vitro
(13). In addition, it has been
documented that Smad3 knockout mice have an increased proliferation rate when
stimulated with FBS or with platelet-derived growth factor compared with
wild-type HSCs (28). It is
expected that Smad3 is necessary for inhibition of culture-activated HSC
proliferation. Therefore, alteration of Smad1 gene expression by TGF-
1
may strengthen the role of Smad3 or Smad2 in TGF-
signal transduction,
which may determine HSC responses to TGF-
1.
Although TGF-
downregulation of Smad1 in HSCs may be of benefit to
TGF-
profibrogenic action on HSCs, it may also alter the
transdifferentiation of HSCs. Since Smad1 expression is increased during
transdifferentiation of HSCs and BMP2 is more potent in induction of
-SMA (a transdifferentiation marker of HSCs) than TGF-
1, the
reduction of Smad1 could interfere with the transdifferentiation of HSCs. This
may ultimately alter the response of HSCs to TGF-
1. In addition,
TGF-
1 can activate the Smad1 signaling pathway, Smad2/Smad3 signaling,
and the MAPK pathway (21).
TGF-
1 inhibition of Smad1 gene expression could inhibit the signaling
events mediated by Smad1 while strengthening the signaling events mediated by
the other signaling molecules. Therefore, the findings in our study indicate
complex effects of TGF-
on HSCs.
In conclusion, we have documented that Smad1 mRNA and protein are elevated
during in vitro activation of HSCs and that TGF-
1 downregulates Smad1
mRNA and protein in HSCs. These findings reveal an important role of Smad1 in
HSC activation and an important molecular mechanism in Smad1 gene regulation.
In addition, TGF-
downregulation of Smad1 may be important in the
balance of different TGF-
biological effects.
 |
DISCLOSURES
|
---|
This work was supported by grants from the Canadian Institute of Health
Research, The University of Manitoba, and the Manitoba Medical Service
Foundation. G. Huang was the recipient of postdoctoral fellowship from the
Health Sciences Centre Foundation, Winnipeg, Manitoba, Canada.
 |
FOOTNOTES
|
---|
Address for reprint requests and other correspondence: Y. Gong, Faculty of
Pharmacy, Univ. of Manitoba, 304-50 Sifton Rd., Winnipeg, MB R3T 2N2 Canada
(E-mail:
ygong{at}ms.umanitoba.ca).
Current address for Y. Chen: First Affiliated Hospital of WenZhou Medical
College, WenZhou, Zhejiang, People's Republic of China (E-mail:
chenyp{at}wz.zj.cn).
The costs of publication of this article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
 |
REFERENCES
|
---|
- Attisano L and
Wrana JL. Smads as transcriptional co-modulators. Curr Opin
Cell Biol 12:
235-243, 2000.[ISI][Medline]
- Brenner DA,
Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M,
Gillan A, and Rippe RA. New aspects of hepatic fibrosis. J
Hepatol 32:
32-38, 2000.
- Chang H,
Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, and Zwijsen A. Smad5
knockout mice die at mid-gestation due to multiple embryonic and
extraembryonic defects. Development
126: 1631-1642,
1999.[Abstract/Free Full Text]
- Clouthier DE,
Comerford SA, and Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a
lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J
Clin Invest 100:
2697-2713, 1997.[Abstract/Free Full Text]
- Davis BH, Rapp
UR, and Davidson NO. Retinoic acid and transforming growth factor beta
differentially inhibit platelet-derived-growth-factor-induced Ito-cell
activation. Biochem J 278:
43-47, 1991.[ISI][Medline]
- Dooley S,
Delvoux B, Lahme B, Mangasser-Stephan K, and Gressner AM. Modulation of
transforming growth factor beta response and signaling during
transdifferentiation of rat hepatic stellate cells to myofibroblasts.
Hepatology 31:
1094-1106, 2000.[ISI][Medline]
- Dooley S,
Streckert M, Delvoux B, and Gressner AM. Expression of Smads during in
vitro transdifferentiation of hepatic stellate cells to myofibroblasts.
Biochem Biophys Res Commun 283:
554-562, 2001.[ISI][Medline]
- Friedman SL. Hepatic stellate cells. Prog Liver
Dis 14: 101-130,
1996.[Medline]
- Fryer HJ, Davis
GE, Manthorpe M, and Varon S. Lowry protein assay using an automatic
microtiter plate spectrophotometer. Anal Biochem
153: 262-266,
1986.[ISI][Medline]
- George J,
Roulot D, Koteliansky VE, and Bissell DM. In vivo inhibition of rat
stellate cell activation by soluble transforming growth factor beta type II
receptor: a potential new therapy for hepatic fibrosis. Proc Natl
Acad Sci USA 96:
12719-12724, 1999.[Abstract/Free Full Text]
- Gong W, Pecci
A, Roth S, Lahme B, Beato M, and Gressner AM. Transformation-dependent
susceptibility of rat hepatic stellate cells to apoptosis induced by soluble
Fas ligand. Hepatology 28:
492-502, 1998.[ISI][Medline]
- Gong Y, Deng S,
Zhang M, Wang G, Minuk GY, and Burczynski F. A cyclin-dependent kinase
inhibitor (p21WAF1/CIP1) affects thymidine incorporation in human
liver cancer cells. Br J Cancer
86: 625-629,
2002.[ISI][Medline]
- Hellerbrand C,
Stefanovic B, Giordano F, Burchardt ER, and Brenner DA. The role of
TGFbeta1 in initiating hepatic stellate cell activation in vivo. J
Hepatol 30:
77-87, 1999.[ISI][Medline]
- Huang S,
Flanders KC, and Roberts AB. Characterization of the mouse Smad1 gene and
its expression pattern in adult mouse tissues. Gene
258: 43-53,
2000.[ISI][Medline]
- Itoh S, Itoh F,
Goumans MJ, and Ten Dijke P. Signaling of transforming growth factor-beta
family members through Smad proteins. Eur J Biochem
267: 6954-6967,
2000.[Abstract/Free Full Text]
- Kanzler S,
Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum
Buschenfelde KH, and Blessing M. TGF-beta1 in liver fibrosis: an inducible
transgenic mouse model to study liver fibrogenesis. Am J Physiol
Gastrointest Liver Physiol 276:
G1059-G1068, 1999.[Abstract/Free Full Text]
- Kretzschmar M,
Doody J, and Massague J. Opposing BMP and EGF signalling pathways converge
on the TGF-beta family mediator Smad1. Nature
389: 618-622,
1997.[ISI][Medline]
- Kretzschmar M,
Liu F, Hata A, Doody J, and Massague J. The TGF-beta family mediator Smad1
is phosphorylated directly and activated functionally by the BMP receptor
kinase. Genes Dev 11:
984-995, 1997.[Abstract]
- Liu F, Hata A,
Baker JC, Doody J, Carcamo J, Harland RM, and Massague J. A human Mad
protein acting as a BMP-regulated transcriptional activator.
Nature 381:
620-623, 1996.[ISI][Medline]
- Liu X, Yue J,
Frey RS, Zhu Q, and Mulder KM. Transforming growth factor beta signaling
through Smad1 in human breast cancer cells. Cancer Res
58: 4752-4757,
1998.[Abstract]
- Massague J.
How cells read TGF-beta signals. Nat Rev Mol Cell Biol
1: 169-178,
2000.[ISI][Medline]
- Massague J and
Wotton D. Transcriptional control by the TGF-beta/Smad signaling system.
EMBO J 19:
1745-1754, 2000.[Abstract/Free Full Text]
- Miyazono K, ten
Dijke P, and Heldin CH. TGF-beta signaling by Smad proteins.
Adv Immunol 75:
115-157, 2000.[ISI][Medline]
- Queva C,
McArthur GA, Ramos LS, and Eisenman RN. Dwarfism and dysregulated
proliferation in mice overexpressing the MYC antagonist MAD1. Cell
Growth Differ 10:
785-796, 1999.[Abstract/Free Full Text]
- Reeves HL and
Friedman SL. Activation of hepatic stellate cells-a key issue in liver
fibrosis. Front Biosci 7:
d808-d826, 2002.[ISI][Medline]
- Rosendahl A,
Pardali E, Speletas M, Ten Dijke P, Heldin CH, and Sideras P. Activation
of bone morphogenetic protein/Smad signaling in bronchial epithelial cells
during airway inflammation. Am J Respir Cell Mol Biol
27: 160-169,
2002.[Abstract/Free Full Text]
- Saile B,
Matthes N, Knittel T, and Ramadori G. Transforming growth factor beta and
tumor necrosis factor alpha inhibit both apoptosis and proliferation of
activated rat hepatic stellate cells. Hepatology
30: 196-202,
1999.[ISI][Medline]
- Schnabl B,
Kweon YO, Frederick JP, Wang XF, Rippe RA, and Brenner DA. The role of
Smad3 in mediating mouse hepatic stellate cell activation.
Hepatology 34:
89-100, 2001.[ISI][Medline]
- Shen H, Zhang
M, Minuk GY, and Gong Y. Different effects of rat interferon alpha, beta
and gamma on rat hepatic stellate cell proliferation and activation.
BMC Cell Biol 3:
9, 2002.[Medline]
- Shi Y, Katsev
S, Cai C, and Evans S. BMP signaling is required for heart formation in
vertebrates. Dev Biol 224:
226-237, 2000.[ISI][Medline]
- Wrana JL.
Crossing Smads. Sci STKE 2000:
RE1, 2000.
- Wrana JL.
Regulation of Smad activity. Cell
100: 189-192,
2000.[ISI][Medline]
- Wrana JL and
Attisano L. The Smad pathway. Cytokine Growth Factor
Rev 11: 5-13,
2000.[ISI][Medline]
- Yata Y, Gotwals
P, Koteliansky V, and Rockey DC. Dose-dependent inhibition of hepatic
fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic
therapy. Hepatology 35:
1022-1030, 2002.[ISI][Medline]
- Yue J and
Mulder KM. Requirement of Ras/MAPK pathway activation by transforming
growth factor beta for transforming growth factor beta 1 production in a
Smad-dependent pathway. J Biol Chem
275: 30765-30773,
2000.[Abstract/Free Full Text]
Copyright © 2003 by the American Physiological Society.